# EU-1-21-1617_public-assessment-report_20220311_20220311_ngenla-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
16 December 2021
EMA/15620/2022
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Ngenla
International non-proprietary name: somatrogon
Procedure No. EMEA/H/C/005633/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.
Administrative information
Name of the medicinal product:
Ngenla
Applicant:
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
BELGIUM
Active substance:
somatrogon
International Non-proprietary Name/Common
Name:
somatrogon
Pharmaco-therapeutic group
(ATC Code):
Subject to final ATC code
Therapeutic indication(s):
Ngenla is indicated for the treatment of
children and adolescents from 3 years of age
with growth disturbance due to insufficient
secretion of growth hormone.
Pharmaceutical form(s):
solution for injection
Strength(s):
24 mg/ 1.2 ml and 60 mg/ 1.2 ml
Route(s) of administration:
subcutaneous use
Packaging:
cartridge (glass) in a pre-filled pen
Package size(s):
1 pre-filled pen
Assessment report
EMA/15620/2022
Page 2/127
